K. Boxall

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
K. Boxall, Katherine Boxall, Kathy J Boxall, Katherine J. Boxall, K Boxall, Katherine J Boxall, Kathy Boxall, Kathy J. Boxall
Publication record
75 papers · 3,098 citations · H-index 27

PAPERS

Correction: A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D
20200 citationsauthor #6
2-Arylamino-6-ethynylpurines are cysteine-targeting irreversible inhibitors of Nek2 kinase
202015 citationsauthor #4
Correction: In vitro Biological Characterization of a Novel, Synthetic Diaryl Pyrazole Resorcinol Class of Heat Shock Protein 90 Inhibitors.
20194 citationsauthor #2
Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).
201632 citationsauthor #10
Multi-parameter lead optimization to give an oral CHK1 inhibitor clinical candidate: (R)-5-((4-((morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)
20160 citationsauthor #13
Structure-guided design of purine-based probes for selective Nek2 inhibition
201614 citationsauthor #4
8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors
201685 citationsauthor #10
Abstract 2843: Resistance to ERK inhibitors as a result of an acquired novel P-loop mutation of ERK2
20150 citationsauthor #5
Abstract 5450: Naturally occurring mutations in the MPS1 gene predispose cells to kinase inhibitor drug-resistance
201530 citationsauthor #9
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma
201558 citationsauthor #8
Design of potent and selective hybrid inhibitors of the mitotic kinase Nek2: SAR, structural biology and cellular activity
20145 citationsauthor #8
PKA-S6K1 Chimera Apo
20130 citationsauthor #6
Structure-based design of orally bioavailable pyrrolopyridine inhibitors of the mitotic kinase MPS1
20130 citationsauthor #12
PKA-S6K1 Chimera with compound 21a (CCT196539) bound
20130 citationsauthor #6
PKA-S6K1 Chimera with compound 15e (CCT147581) bound
20130 citationsauthor #6
PKA-S6K1 Chimera with Staurosporine bound
20130 citationsauthor #6
PKA-S6K1 Chimera with compound 21e (CCT239066) bound
20130 citationsauthor #6
Aurora Isoform Selectivity: Design and Synthesis of Imidazo [4, 5-b] pyridine Derivatives as Highly
201347 citationsauthor #10
Structure-Based Design of Orally Bioavailable 1H-Pyrrolo[3,2-c]pyridine Inhibitors of Mitotic Kinase Monopolar Spindle 1 (MPS1)
201366 citationsauthor #13
PKA-S6K1 Chimera with compound 1 (NU1085) bound
20130 citationsauthor #6
Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2)
20130 citationsauthor #3
Fragment-Based Screening Maps Inhibitor Interactions in the ATP-Binding Site of Checkpoint Kinase 2
201325 citationsauthor #3
Aurora Isoform Selectivity: Design and Synthesis of Imidazo[4,5-b]pyridine Derivatives as Highly Selective Inhibitors of Aurora-A Kinase in Cells
201317 citationsauthor #10
The discovery of potent ribosomal S6 kinase inhibitors by high-throughput screening and structure-guided drug design
201323 citationsauthor #6
118 2-arylamino-6-ethynylpurines as Potent Irreversible Inhibitors of the Mitotic Kinase Nek2
20124 citationsauthor #3
Design of potent and selective hybrid inhibitors of the mitotic kinase Nek2: structure-activity relationship, structural biology, and cellular activity.
201259 citationsauthor #7
Discovery of 3-Alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as Selective, Orally Bioavailable CHK1 Inhibitors
201231 citationsauthor #4
CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs
201292 citationsauthor #9
Co-crystal structure of a small molecule inhibitor bound to the kinase domain of Chk2
20110 citationsauthor #6
Structure-Guided Evolution of Potent and Selective CHK1 Inhibitors through Scaffold Morphing
201157 citationsauthor #13
Abstract A235: Structure-guided evolution of potent and selective oral inhibitors of CHK1 through scaffold morphing.
20110 citationsauthor #9
Benzimidazole inhibitors induce a DFG-out conformation of never in mitosis gene A-related kinase 2 (Nek2) without binding to the back pocket and reveal a nonlinear structure-activity relationship.
201151 citationsauthor #4
Structure-based design of potent and selective 2-(quinazolin-2-yl)phenol inhibitors of checkpoint kinase 2.
201146 citationsauthor #6
Abstract A228: CCT244747 is a novel, potent and selective inhibitor of CHK1 with oral efficacy both alone in neuroblastoma and in combination with genotoxic chemotherapeutic agents.
20110 citationsauthor #9
Is a Potent and Selective Inhibitor of CHK 2 that Potentiates the Cytotoxicity of PARP Inhibitors
20110 citationsauthor #4
CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors.
2011102 citationsauthor #4
Structure of a small molecule inhibitor with the kinase domain of Chk2
20111 citationsauthor #6
Corrigendum to "Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2" [Bioorg. Med. Chem. 18 (2010) 707] (DOI:10.1016/j.bmc.2009.11.058)
20100 citationsauthor #4
Corrigendum to “Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2” [Bioorg. Med. Chem. 18 (2010) 707]
20105 citationsauthor #4
Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2.
201055 citationsauthor #4
Design and evaluation of 3,6-di(hetero)aryl imidazo[1,2-a]pyrazines as inhibitors of checkpoint and other kinases.
201022 citationsauthor #4
The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106
201090 citationsauthor #7
Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2 (vol 18, pg 707, 2010)
20101 citationsauthor #4
Aminopyrazine Inhibitors Binding to an Unusual Inactive Conformation of the Mitotic Kinase Nek2: SAR and Structural Characterization†
201070 citationsauthor #6
Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors
20090 citationsauthor #4
Molecular Cancer Therapeutics The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK 1 Inhibitor SAR-020106
20090 citationsauthor #7
CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
20090 citationsauthor #4
Identification of inhibitors of checkpoint kinase 1 through template screening.
200941 citationsauthor #4
NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis.
2008466 citationsauthor #16
A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D
200890 citationsauthor #6
A duplexed phenotypic screen for the simultaneous detection of inhibitors of the molecular chaperone heat shock protein 90 and modulators of cellular acetylation
200713 citationsauthor #6
NVP-AUY922, a novel diarylisoxazole resorcinol HSP90 inhibitor, potently inhibits growth and metastasis of human tumor xenografts
20070 citationsauthor #7
Synthetic ansamycins prepared by a ring-expanding Claisen rearrangement. Synthesis and biological evaluation of ring and conformational analogues of the Hsp90 molecular chaperone inhibitor geldanamycin.
200716 citationsauthor #6
4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer.
2007426 citationsauthor #5
In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors.
2007109 citationsauthor #2
Inhibition of the HSP90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole, isoxazole amide analogs
20070 citationsauthor #3
Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues
2007130 citationsauthor #3
Inhibition of Hsp90 with synthetic macrolactones: synthesis and structural and biological evaluation of ring and conformational analogs of radicicol.
200664 citationsauthor #3
Trans‐activation of the DNA‐damage signalling protein kinase Chk2 by T‐loop exchange
2006146 citationsauthor #3
The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors.
2005206 citationsauthor #5
Solid-Phase Immunoassays in Mechanism-Based Drug Discovery: Their Application in the Development of Inhibitors of the Molecular Chaperone Heat-Shock Protein 90
200516 citationsauthor #2
Human Hsp90-alpha with 8-(2,5-dimethoxy-benzyl)-2-fluoro-9-pent-9H-purin-6-ylamine
20040 citationsauthor #14
Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms.
2004237 citationsauthor #14
Mechanism of action of a novel series of inhibitors of the Hsp90 molecular chaperone
20041 citationsauthor #6
Human Hsp90-alpha with 8-Benzo[1,3]dioxol-,5-ylmethyl-9-butyl-2-fluoro-9H-purin-6-ylamine
20040 citationsauthor #14
Human Hsp90-alpha with 8-Benzo[1,3]dioxol-,5-ylmethyl-9-butyl-9H-purin-6-ylamine
20040 citationsauthor #14
Human Hsp90-alpha with 8-(2,5-dimethoxy-benzyl)-2-fluoro-9H-purin-6-ylamine
20040 citationsauthor #14
Human Hsp90-alpha with 9-Butyl-8-(2-chloro-3,4,5-trimethoxy-benzyl)-9H-purin-6-ylamine
20040 citationsauthor #14
347 Biological evaluation of a novel, synthetic pyrazole class of Hsp90 inhibitors
20042 citationsauthor #2
Human Hsp90-alpha with 8-(2-chloro-3,4,5-trimethoxy-benzyl)-2-fluoro-9-pent-4-ylnyl-9H-purin-6-ylamine
20040 citationsauthor #14
Human Hsp90-alpha with 9-Butyl-8-(3,4,5-trimethoxy-benzyl)-9H-purin-6-ylamine
20040 citationsauthor #14
Human Hsp90-alpha with 9-Butyl-8-(2,5-dimethoxy-benzyl)-2-fluoro-9H-purin-6-ylamine
20040 citationsauthor #14
Human Hsp90-beta with PU3 (9-Butyl-8(3,4,5-trimethoxy-benzyl)-9H-purin-6-ylamine)
20040 citationsauthor #14
Induction of Hsp70 and depletion of the client protein c-Raf-1 measured by ELISA following cellular exposure to the novel Hsp90 ATPase inhibitor, CCT018159
20032 citationsauthor #3
Assays for HSP90 and inhibitors.
200327 citationsauthor #6

TIMELINE

2003 29 citations

2004 240 citations

2005 222 citations

2006 210 citations

2007 694 citations

2008 556 citations

2009 41 citations

2010 243 citations

2011 257 citations

2012 186 citations

2013 178 citations

2014 5 citations

2015 88 citations

2016 131 citations

2019 4 citations

2020 15 citations

COAUTHOR MAP

CONCEPT FOOTPRINT